Components
Community claim
GLOW-like effects plus anti-inflammatory claims.
Community and market provenance
Community mention, not clinical evidence
- Source: pdf01 · Page 4
- Source: pdf03 · Page 2
- Source: pdf04 · Page 1
- Source: pdf05 · Page 4
- Source: pdf06 · Page 2
- Source: pdf06 · Page 4
- Source: pdf07 · Page 4
- Source: pdf08 · Page 6
- Source: pdf09 · Page 2
- Source: img01 · Page 1
- Source: img03 · Page 1
- Source: img04 · Page 1
- Source: img08 · Page 1
Evidence of the exact combination
No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.
Component links are not combination evidence. A commercial name’s composition may vary.
Uncertainty and risks
STELLA p1 lists KLOW70 with three components, while KLOW lists four. SinoPep lists variants without compositions. Never infer KPV solely from the name.
Observed in supplier/community material; prevalence not quantified.
No dosing or mixing instructions are provided.
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID36588717
He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M.
October 16, 2026
- R01
- R02
- R03
- R06
- R07
- R08
- R09
- R14
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026